University spin outs nominated for top Scottish Enterprise awards

University spin outs nominated for top Scottish Enterprise awards

Two businesses developed out of University of Aberdeen research, and another that is set to be spun out in the future, have been nominated for prestigious Scottish Enterprise Life Science Awards.

Novabiotics Ltd and SIRAKOSS Ltd have been listed as one of the final four in the Investment of the Year category.

Meanwhile, Ripptide Pharma Ltd, a pre-spin out company, is in line to pick up the Innovation Award.

The Scottish Enterprise Life Sciences Awards recognise the achievements of individuals, companies and research organisations within the Scottish life sciences sector during the previous year.

About the companies:

NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The company was founded by Dr Deborah O’Neill and Professor Andrew Porter is a member of the board.

SIRAKOSS Ltd develops materials that mimic bone - producing purely synthetic material, with no variability in performance and has the potential to treat patients who need spinal fusion surgery for back pain, or repairs for traumatic bone injuries. Professor Iain Gibson is a co-founder of the firm.

Ripptide Ltd have developed a revolutionary new method for creating a new class of therapeutic drugs, called macrocycles, which are complex to create and can address a large number of poorly treated conditions. Ripptide was co-founded by Professor Marcel Jaspars from the University of Aberdeen and Professor Jim Naismith from the University of St Andrews.

The award ceremony will take place at the National Museum of Scotland on Thursday February 4, 2016.